m Inner Network latest data shows that in the first half of 2022, the sales scale of terminal chemical drugs in public hospitals in key provinces and cities exceeded 100 billion yuan, a slight decline from the same period last year. 228 brands sold over 100 million yuan, with a total sales volume of more than 50 billion yuan. Among them, 98 brands rose sharply against the trend, with sales increasing by more than 10% over the same period last year, including 52 domestic brands and 46 imported brands.
2022 In the first half of 2022, the number of terminals of public hospitals in key provinces and cities exceeded 100 million.
0. Source: Minnei.com. The terminal competition pattern of public hospitals in key provinces and cities
98 brands cover 12 major treatment categories, focusing on anti-tumor and immunomodulatory agents, systemic anti-infective drugs, blood and hematopoietic system drugs, digestive system and metabolic drugs, etc. The terminal sales scale of these four major treatment categories in 2022H1 in key provinces and cities exceeded 10 billion yuan.
10 brands have sales of more than 500 million yuan. Shijiao Group has won three of the four domestic brands, namely PEGylated recombinant human granulocyte stimulator factor injection, paclitaxel for injection (albumin-binding type) and thylphthalide sodium chloride injection; among the 6 imported brands, Jeterbelin's human albumin leads with more than 800 million yuan, and sales of AstraZeneca 's osimertinib methanesulfonate tablets, Pfizer 's cefoperidone sodium sulbactam sodium (2:1) and other products have exceeded 700 million yuan.
15 brands rose by more than 100%. Among the 9 domestic brands, Yichang Dongyangguang Changjiang Pharmaceutical 2's oseltamivir phosphate granules ranked first with a growth rate of 656.1%, Hainan Xiansheng Pharmaceutical's Edarafen dextopentanol injection concentrated solution and BeiGene 's tirelizumab injection both increased by more than 300%. Among the 6 imported brands, Biogen's Nocinarin sodium injection ranked first with a growth rate of 852.13%, Xi'an Janssen 's Daratumab injection, Sanofi 's duprilizumab injection, and Eli Lilly's dula glycopeptide injection all increased by more than 400%.
domestic brands: Shiyao leads, Hausen , Xiansheng and other new drugs in Class 1 have increased
52 domestic brands involve 38 pharmaceutical companies (in terms of the group), Shiyao Group monopolizes 4 brands, China Biopharma , Shangyao Group, and Yuanda Health have 3 brands listed, BeiGene, Enhua Pharmaceutical, Fosun Pharmaceutical , Health Yuan , Xiansheng Pharmaceutical , Shijiazhuang Four Medicines , Shijiazhuang Four Medicines have 2 brands listed.
has a growth rate of more than 10% and over 100 million. The domestic brands have reached 3 or more pharmaceutical companies. Among the four brands of
, 3 of the 4 brands of Shiyao Pharmaceutical have sales exceeding 500 million yuan in 2022H1. Among them, phthalide sodium chloride injection is the exclusive variety of the company. In addition, it dominates the two major varieties of paclitaxel (albumin-binding type) and pegylated recombinant human granulocyte stimulation factor injection.
Among the three brands of China's biopharmaceuticals, magnesium isoligeryl isoglycyrrhizate injection is the exclusive variety of Zhengdatianqing , with sales exceeding 400 million yuan in 2022H1; abiraterone acetate tablets are the second batch of nationally purchased varieties, and Zhengdatianqing was selected as the first ranking. In recent years, sales in public hospital terminals in key provinces and cities have increased year by year.
Among the three brands of Shangyao Group, colistin sulfate for injection and polymyxin sulfate for injection can be used for drug-resistant bacteria infection, and the company is dominant in the market structure; among the 23 brands of , indobufen tablets are the exclusive variety, and the sales growth rate of 2022H1 is close to 70%. Among the top 10 domestic brands,
52 domestic brands, sales growth rate of
, 9 of them rose by more than 100%. Yichang Dongyangguang Changjiang Pharmaceutical's oseltamivir phosphate granules led the company with a growth rate of 656.10%. This is the company's exclusive dosage form variety. After the downturn in the previous two years, the market began to warm up; Hainan Xiansheng Pharmaceutical's Edaravone dextopentanol injection concentrated solution, BeiGene's tirelizumab injection and Zebutinib capsules, Zai Lab Pharmaceutical's 's niraparib toluenesulfonate capsules, Hausen Pharmaceutical's 's ametinib mesylate tablets and other domestic 1 new drugs in 2022H1 sales growth rate exceeds 200%.
imported brands: AstraZeneca and Pfizer dominate the screen, and the six major brands have risen by more than 100%
46 imported brands involve 21 pharmaceutical companies (in terms of the group), AstraZeneca and Pfizer both exclusively occupy 6 brands, Bayer has 4 brands, and Roche, Merck and Novartis have 3 brands.
Growth rate exceeds 10% and over 100 million imported brands reach 4 or more pharmaceutical companies
Source: Minnei.com Key provinces and cities public hospital terminal competition pattern
Source: Minnei.com Key provinces and cities public hospital terminal competition pattern
